Side Effects of Cytokines Approved for Therapy

Abstract

Cytokines, currently known to be more than 130 in number, are small MW (<30 kDa) key signaling proteins that modulate cellular activities in immunity, infection, inflammation and malignancy. Key to understanding their function is recognition of their pleiotropism and often overlapping and functional redundancies. Classified here into 9 main families, most of the 20 approved cytokine preparations (18 different cytokines; 3 pegylated), all in recombinant human (rh) form, are grouped in the hematopoietic growth factor, interferon, platelet-derived growth factor (PDGF) and transforming growth factor β (TGFβ) families. In the hematopoietin family, approved cytokines are aldesleukin (rhIL-2), oprelvekin (rhIL-11), filgrastim and tbo-filgrastim (rhG-CSF), sargramostim (rhGM-CSF), metreleptin (rh-leptin) and the rh-erythropoietins, epoetin and darbepoietin alfa. Anakinra, a recombinant receptor antagonist for IL-1, is in the IL-1 family; recombinant interferons alfa-1, alfa-2, beta-1 and gamma-1 make up the interferon family; palifermin (rhKGF) and becaplermin (rhPDGF) are in the PDGF family; and rhBMP-2 and rhBMP-7 represent the TGFβ family. The main physicochemical features, FDA-approved indications, modes of action and side effects of these approved cytokines are presented. Underlying each adverse events profile is their pleiotropism, potency and capacity to release other cytokines producing cytokine 'cocktails'. Side effects, some serious, occur despite cytokines being endogenous proteins, and this therefore demands caution in attempts to introduce individual members into the clinic. This caution is reflected in the relatively small number of cytokines currently approved by regulatory agencies and by the fact that 14 of the FDA-approved preparations carry warnings, with 10 being black box warnings.

Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in Liver

“…Treatment with recombinant leptin therapy through subcutaneous injection produces short-lasting effects and therefore requires repetitive doses. The supra-physiological increase in circulating leptin level following regular injection is associated with serious side effects 37 . Gene therapies with AAV vectors have been attempted in ob/ob mice, an animal model best recapitulating human congenital leptin deficiencies.…”

Decoupling the Functional Pleiotropy of Stem Cell Factor by Tuning c-Kit Signaling

“…Pleiotropic actions can induce counterbalancing cellular activities, resulting in blunted therapeutic efficacy (Hart et al, 2014; Lin et al, 1995). Furthermore, pleiotropy exacerbates off-target toxicities through activation of undesired cell types (Baldo, 2014; Krieg et al, 2010). Previous studies have shown that natural and engineered ligands, which modulate receptor dimerization by altering receptor-ligand complex stability, affinity and/or geometry, have the capacity to modulate downstream signaling outputs and target cell selectivity (Levin et al, 2014; Macdonald-Obermann and Pike, 2014; Mitra et al, 2015; Moraga et al, 2015a; Moraga et al, 2015b; Riese, 2011; Yea et al, 2015).…”

Lentinan mitigates therarubicin-induced myelosuppression by activating bone marrow-derived macrophages in an MAPK/NF-κB-dependent manner

“…Combination therapy with rhG-CSF is commonly used to mitigate THP-induced granulocytopaenia in the clinic. However, rhG-CSF combination therapy is expensive and associated with multiple side-effects (22). Therefore, new strategies to prevent or reduce the toxicity of chemotherapy at the level of haematopoiesis are essential to improve therapeutic outcome Figure 6.…”

“…LNT is a β-D-glucan extracted from shiitake mushrooms (Lentinus edodes). A role for LNT in regulating the immune system has been implicated both in vivo and in vitro by several studies (13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Moreover, LNT has antitumour (23), antioxidation (24) and DNA damage repair activities (12).…”